Optimal Pharmacologic Treatment of ADPKD: What You Need to Know
| Overview / Abstract: |
This activity consists of three related modules on the pharmacologic management of patients with ADPKD. The modules follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In this 1.5 hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of case studies with text, faculty and patient videos, and evidence-based animated slides. |
|
Expiration |
Jun 17, 2022 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online |
|
Credits / Hours |
1.5 |
|
Accreditation |
ACCME, ANCC, ACPE |
|
Presenters / Authors / Faculty |
Neera Dahl, MD, PhD, Gary Israel, MD, Lena DeVietro, PharmD |
|
Activity Specialities / Related Topics |
Primary Care, Pharmacology, Nephrology |
|
Sponsors / Supporters / Grant Providers |
Otsuka America Pharmaceutical, Inc. |
|
Keywords / Search Terms |
ADPKD, autosomal dominant polycystic kidney disease, polycystic kidney disease, REMS, risk evaluation and mitigation strategy, elements to assure safe use, tolvaptan, nephrology, radiology, specialty pharmacy, kidney function decline, renal cysts, kidney size, kidney volume measurement, height-adjusted total kidney volume, Mayo imaging classification model, ESKD, ACPE, pharmacy credit, physician CME, ANCC, medical education |
|